Related Experiment Video
Updated: Jun 1, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Substituting warfarin products: what's the source of the problem?
1Department of Pharmacy Practice and Science, School of Pharmacy, University of Maryland, Baltimore, MD. shaines@rx.umaryland.edu
The Annals of Pharmacotherapy
|June 14, 2011
Summary
Concerns about warfarin product bioequivalence are widespread, but clinical trials show no increased risk of bleeding or clots when switching brands. The variability in anticoagulation control remains similar, suggesting other factors like communication errors are the true cause.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Patient Safety
Background:
- Clinicians express concerns regarding warfarin product bioequivalence.
- Anecdotal reports and retrospective studies suggest warfarin substitution may increase risks of bleeding and thromboembolic events.
Purpose of the Study:
- To evaluate the clinical impact of warfarin product substitution on anticoagulation control and patient safety.
- To determine if differences in warfarin product bioequivalence contribute to adverse events.
Main Methods:
- Review of prospective, randomized, blinded clinical trials.
- Analysis of interpatient and intrapatient variability in anticoagulation control before and after warfarin product substitution.
Main Results:
- Prospective, randomized, blinded trials failed to validate concerns about increased risks with warfarin product substitution.
- Interpatient and intrapatient variability in anticoagulation control remained similar regardless of product substitution.
Conclusions:
- The observed variability in anticoagulation control is not explained by differences in warfarin product standardization, bioavailability, or bioequivalence.
- Poor communication, fragmented care systems, and medical errors are potential explanations for perceived issues with warfarin product substitution.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...